Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?
We Think Yes..!
With the year just finished ringing in $17.8 million in revenues, versus a market capitalization of...
Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.
If we average out the two most recent price targets this month, we come out with a potential gain of 337% and...
Hidden Gem and a Monster in the Making? Beasley Broadcast Group (BBGI) $0.80
If They Simply Changed Their Name to Beasley Internet Group, it Could be Revalued 3-Fold Higher.
We...
Report: Think Equity Updates Society Pass (SOPA). $6.00 Price Target.
Think Equity: Society Pass (Nasdaq: SOPA) – Path to Profitability
NEW YORK, NY, March 14, 2023 (GLOBE NEWSWIRE) --...
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.
Interview: Rokas Sidlauskas, Marketing Director of Society Pass (SOPA)
Shares Roadmap to Expand the Society Pass (SoPa Group) Ecosystem in South East Asia.
Related News
Meet Dennis Nguyen CEO of Start-Up Investor, the Society Pass (Symbol: SOPA)
See a Dazzling Presentation!
Society Pass (SOPA) has quickly acquired 8 companies since going public in late 2021,...
Freedom Holding (FRHC) Acquires LD Micro From SRAX, Inc
Purchase brings pre-eminent small-cap platform to the Freedom family
Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp....
EyeOnChannel.com
Eye on Channel is a digital video giant that connects millions of viewers to targeted and preferred demographics in destinations including Boston,...
Institutional Analyst: Our #1 Internet Company, Society Pass (Nasdaq: SOPA), Holds Appeal for Both...
Press Release:
February 28, 2023 07:30 ET | Source: Society Pass Incorporated
New York,...
Latest article
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of...
